Thomas Burke Ph.D provides a PDF on nitric oxide and diabetes. Nitric oxide (NO), is a free radical gas that is a powerful regulator of circulation (it is an endogenous vasodilator) and a neurotransmitter (it helps in the processing of nerve signals as they cross synapses). L-arginine, one of 20 …

Statins in renal disease: ezetimibe and fibric acid drugs.

Female, 58 years of age. On a daily GLP-1 agonist, SGLT-2, metformin, not reaching goal. Started long-acting insulin, using insulin pen. Some improvements, but post prandials still elevated.

In this week's Homerun Slides, approaches to intensifying therapy in patients who are using basal insulin but are not yet at goal.

This week our Home Run Slides lay out a roadmap for insulin intensification, and the use of GLP-1 analogs and DPP4-I with insulin. If you follow the path your patients can safely intensify therapy with a greatly reduced risk of hypoglycemia. You can learn even more about all the different …

Dr. Paresh Dandona, Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at the University of Buffalo, The State University of New York, continues his discussion with Associate Medical Editor Joy Pape at the 2015 ADA Sessions in Boston. This week, he shares his thoughts on the greatest advancements in diabetes care.

A 47 year-old patient has done an excellent job with lifestyle modifications and medication adherence, however she has not been able to yet achieve her individualized A1C goal. Her current regimen consists of a metformin, sitagliptin and insulin detemir (insulin started 4 months prior). However, over the past month as she has titrated her basal insulin towards her A1C goal, her self-glucose blood monitoring log shows large drops in her overnight glucose levels. After consulting with the treatment team, you decide to add rapid-acting prandial insulin to her regimen. How would you implement this strategy? Follow the link to take the quiz!

Treatment showed statistically significant improvements in pain relief and sleep quality.

Treatment found to reduce incidence of adenomas in patients with seemingly dose-dependent effect.

Closed-loop system at home over 12 weeks feasible in type 1 patients.